CD28 and neoplasm: Its interaction with ligands PD-L1 (CD274) and PD-L2, expressed on tumor cells and immune cells within the tumor microenvironment (TME), attenuates T-cell receptor (TCR) signaling and co-stimulatory pathways (e.g., CD28), promoting immune escape [33,34].